Homology model of RSK2 N-terminal kinase domain, structure-based identification of novel RSK2 inhibitors, and preliminary common pharmacophore

Tam Luong Nguyen, Rick Gussio, Jeffrey A. Smith, Deborah A. Lannigan, Sidney Hecht, Dominic A. Scudiero, Robert H. Shoemaker, Daniel W. Zaharevitz

Research output: Contribution to journal › Article

38 Citations (Scopus)

Abstract

Ribosomal S6 kinase 2 (RSK2) is a serine/threonine kinase that plays a role in human cancer and Coffin-Lowry syndrome and is comprised of two nonidentical kinase domains, each domain with its own ATP-binding site. RSK2 can be inactivated by different types of small organic molecules. Potent RSK2 inhibitors include the two classic bisindole maleimide PKC inhibitors, Ro31-8220 and GF109203X, and the natural product SL0101 that was shown to bind specifically to the ATP pocket of the N-terminal domain (NTD). In this paper, we present an atomic model of the RSK2 NTD (residues 68-323), which was built to simultaneously bind the distinctive molecular scaffolds of SL0101, Ro31-8220, and GF109203X. The RSK2 NTD model was used to identify two novel RSK2 inhibitors from the National Cancer Institute open chemical repository and to develop a preliminary structure-based pharmacophore model.

Original languageEnglish (US)
Pages (from-to)6097-6105
Number of pages9
JournalBioorganic and Medicinal Chemistry
Volume14
Issue number17
DOIs
StatePublished - Sep 1 2006
Externally publishedYes

Fingerprint

Phosphotransferases
Coffin-Lowry Syndrome
Adenosine Triphosphate
National Cancer Institute (U.S.)
Protein-Serine-Threonine Kinases
Biological Products
Scaffolds
ribosomal protein S6 kinase, 90kDa, polypeptide 3
Binding Sites
Molecules
Neoplasms
SL0101
Ro 31-8220
bisindolylmaleimide I

Keywords

  • ATP-binding site
  • Homology model
  • Ligand docking
  • Pharmacophore
  • Ribosomal S6 kinase 2
  • Virtual screening

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Organic Chemistry
  • Drug Discovery
  • Pharmaceutical Science

Cite this

Homology model of RSK2 N-terminal kinase domain, structure-based identification of novel RSK2 inhibitors, and preliminary common pharmacophore. / Nguyen, Tam Luong; Gussio, Rick; Smith, Jeffrey A.; Lannigan, Deborah A.; Hecht, Sidney; Scudiero, Dominic A.; Shoemaker, Robert H.; Zaharevitz, Daniel W.

In: Bioorganic and Medicinal Chemistry, Vol. 14, No. 17, 01.09.2006, p. 6097-6105.

Research output: Contribution to journal › Article

Nguyen, TL, Gussio, R, Smith, JA, Lannigan, DA, Hecht, S, Scudiero, DA, Shoemaker, RH & Zaharevitz, DW 2006, 'Homology model of RSK2 N-terminal kinase domain, structure-based identification of novel RSK2 inhibitors, and preliminary common pharmacophore', Bioorganic and Medicinal Chemistry, vol. 14, no. 17, pp. 6097-6105. https://doi.org/10.1016/j.bmc.2006.05.001
Nguyen TL, Gussio R, Smith JA, Lannigan DA, Hecht S, Scudiero DA et al. Homology model of RSK2 N-terminal kinase domain, structure-based identification of novel RSK2 inhibitors, and preliminary common pharmacophore. Bioorganic and Medicinal Chemistry. 2006 Sep 1;14(17):6097-6105. https://doi.org/10.1016/j.bmc.2006.05.001
Nguyen, Tam Luong ; Gussio, Rick ; Smith, Jeffrey A. ; Lannigan, Deborah A. ; Hecht, Sidney ; Scudiero, Dominic A. ; Shoemaker, Robert H. ; Zaharevitz, Daniel W. / Homology model of RSK2 N-terminal kinase domain, structure-based identification of novel RSK2 inhibitors, and preliminary common pharmacophore. In: Bioorganic and Medicinal Chemistry. 2006 ; Vol. 14, No. 17. pp. 6097-6105.
@article{b5ba73ad189c441496d8cabc2bef2176,
title = "Homology model of RSK2 N-terminal kinase domain, structure-based identification of novel RSK2 inhibitors, and preliminary common pharmacophore",
abstract = "Ribosomal S6 kinase 2 (RSK2) is a serine/threonine kinase that plays a role in human cancer and Coffin-Lowry syndrome and is comprised of two nonidentical kinase domains, each domain with its own ATP-binding site. RSK2 can be inactivated by different types of small organic molecules. Potent RSK2 inhibitors include the two classic bisindole maleimide PKC inhibitors, Ro31-8220 and GF109203X, and the natural product SL0101 that was shown to bind specifically to the ATP pocket of the N-terminal domain (NTD). In this paper, we present an atomic model of the RSK2 NTD (residues 68-323), which was built to simultaneously bind the distinctive molecular scaffolds of SL0101, Ro31-8220, and GF109203X. The RSK2 NTD model was used to identify two novel RSK2 inhibitors from the National Cancer Institute open chemical repository and to develop a preliminary structure-based pharmacophore model.",
keywords = "ATP-binding site, Homology model, Ligand docking, Pharmacophore, Ribosomal S6 kinase 2, Virtual screening",
author = "Nguyen, {Tam Luong} and Rick Gussio and Smith, {Jeffrey A.} and Lannigan, {Deborah A.} and Sidney Hecht and Scudiero, {Dominic A.} and Shoemaker, {Robert H.} and Zaharevitz, {Daniel W.}",
year = "2006",
month = "9",
day = "1",
doi = "10.1016/j.bmc.2006.05.001",
language = "English (US)",
volume = "14",
pages = "6097--6105",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "17",

}

TY - JOUR

T1 - Homology model of RSK2 N-terminal kinase domain, structure-based identification of novel RSK2 inhibitors, and preliminary common pharmacophore

AU - Nguyen, Tam Luong

AU - Gussio, Rick

AU - Smith, Jeffrey A.

AU - Lannigan, Deborah A.

AU - Hecht, Sidney

AU - Scudiero, Dominic A.

AU - Shoemaker, Robert H.

AU - Zaharevitz, Daniel W.

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Ribosomal S6 kinase 2 (RSK2) is a serine/threonine kinase that plays a role in human cancer and Coffin-Lowry syndrome and is comprised of two nonidentical kinase domains, each domain with its own ATP-binding site. RSK2 can be inactivated by different types of small organic molecules. Potent RSK2 inhibitors include the two classic bisindole maleimide PKC inhibitors, Ro31-8220 and GF109203X, and the natural product SL0101 that was shown to bind specifically to the ATP pocket of the N-terminal domain (NTD). In this paper, we present an atomic model of the RSK2 NTD (residues 68-323), which was built to simultaneously bind the distinctive molecular scaffolds of SL0101, Ro31-8220, and GF109203X. The RSK2 NTD model was used to identify two novel RSK2 inhibitors from the National Cancer Institute open chemical repository and to develop a preliminary structure-based pharmacophore model.

AB - Ribosomal S6 kinase 2 (RSK2) is a serine/threonine kinase that plays a role in human cancer and Coffin-Lowry syndrome and is comprised of two nonidentical kinase domains, each domain with its own ATP-binding site. RSK2 can be inactivated by different types of small organic molecules. Potent RSK2 inhibitors include the two classic bisindole maleimide PKC inhibitors, Ro31-8220 and GF109203X, and the natural product SL0101 that was shown to bind specifically to the ATP pocket of the N-terminal domain (NTD). In this paper, we present an atomic model of the RSK2 NTD (residues 68-323), which was built to simultaneously bind the distinctive molecular scaffolds of SL0101, Ro31-8220, and GF109203X. The RSK2 NTD model was used to identify two novel RSK2 inhibitors from the National Cancer Institute open chemical repository and to develop a preliminary structure-based pharmacophore model.

KW - ATP-binding site

KW - Homology model

KW - Ligand docking

KW - Pharmacophore

KW - Ribosomal S6 kinase 2

KW - Virtual screening

UR - http://www.scopus.com/inward/record.url?scp=33746049159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746049159&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2006.05.001

DO - 10.1016/j.bmc.2006.05.001

M3 - Article

VL - 14

SP - 6097

EP - 6105

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 17

ER -

Access to Document